Is retatrutide legal to buy in the US?
Updated
Is retatrutide legal to buy? Not in the way a medicine is, and not with a flat yes. Retatrutide is investigational and not FDA-approved, so it cannot be prescribed or dispensed; the clinical routes are Lilly's trials and its expanded access program. Research-grade retatrutide is sold to laboratories for research use only, not as a drug for people.
On this page 9 sections
Is retatrutide legal? The short answer, as of November 12, 2026
The answer to "is retatrutide legal" has three parts, and only the third one concerns a buyer of research material. First, retatrutide is an investigational compound with no FDA approval, so it is not legal to sell or market it as a treatment for anyone. Second, people can only receive it through Eli Lilly's clinical trials or Lilly's expanded access program, both run by physicians. Third, research-grade retatrutide is sold to laboratories for research use only. The FDA judges those sales by intended use rather than by the label alone, so what a seller says matters: no claims about use in people and no dosing.
This page is not legal advice; it is a dated summary of what the FDA, Lilly and ClinicalTrials.gov say, so you can judge for yourself. Prices and vendors are on our where to buy retatrutide page.
See research-grade GLP-3 RT at Astral
Is retatrutide FDA approved?
No. As of November 12, 2026, retatrutide (Lilly code LY3437943) is not approved by the FDA or by any other regulator. Lilly's own July 2026 release describes it as "an investigational molecule that cannot be legally sold or marketed for human use," and its medical information page for physicians, last reviewed in August 2026, states that it is not currently FDA-approved. Those are the developer's words, and they settle the approval question until something changes.
What has changed in 2026 is the timeline. In its July 23, 2026 release on two phase 3 trials, Lilly said it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027, and that it has the clinical data to support submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea. A submission is not an approval; FDA review follows, and Lilly has not announced an approval date.
When will retatrutide be available?
If Lilly files in the first quarter of 2027 as planned, the earliest an approved product could reach pharmacies is after FDA review completes, which has no announced date. Lilly has not published a price either, and it cannot before approval. Our retatrutide price page covers what that means for cost.
Until then, retatrutide exists in three places. It is in Lilly's trials. It is in Lilly's expanded access program for individual patients. And it is in the research market as a reagent sold to laboratories. Only the third is something a buyer can order, and only for research.
Can I buy retatrutide in the US?
A laboratory can. Research suppliers in the United States, including Astral, sell retatrutide as a lyophilized powder for laboratory research only; Astral lists it as GLP-3 RT (Astral's name for retatrutide). The transaction is a sale of a research chemical to a lab, with terms that exclude human use, and the buyer takes on the responsibility that comes with those terms.
A patient cannot, in the sense of buying a medicine. There is no approved product, no pharmacy stock, and no prescription. The two clinical routes both run through a physician. Lilly's phase 3 program is listed on ClinicalTrials.gov, for example NCT05929079 in adults with type 2 diabetes and obesity or overweight, now completed. Lilly's pre-approval expanded access program, listed as NCT07629401 and marked available, lets a treating physician request the compound for an individual adult who meets Lilly's criteria. Lilly says it provides the product at no cost under that program and that the physician, not the patient, initiates the request.
Do you need a prescription for retatrutide?
The question has no good answer because a prescription needs an approved product to name, and there is none. A doctor cannot write a prescription for retatrutide, and a pharmacy could not fill one. A physician who believes a patient qualifies can apply to Lilly's expanded access program, which involves a letter of agreement with Lilly, a patient-specific application to the FDA and institutional review board approval, according to Lilly's medical information page. That is a regulatory process, not a prescription.
Research purchases do not involve a prescription either. A research supplier sells to a laboratory under research-use-only terms, and what it checks is that the buyer is purchasing for research, not that a clinician has authorized anything.
Can you legally buy peptides online?
The research-peptide market sells openly online to laboratories, and research-use-only sales of unapproved compounds are a long-standing category. The line the FDA draws is intended use. The agency's August 24, 2026 warning letter to an online peptide seller names retatrutide among the products. The FDA's position in that letter is that a "research use only" label does not control when the seller's own website describes effects in people; the agency then treats the product as an unapproved new drug intended for human use.
For a buyer, the practical reading is simple. A vendor whose retatrutide page describes effects in people is advertising a drug and inviting that scrutiny. A vendor that names the molecule, states its form and sells it for laboratory research without health claims is doing what a research supplier should. That distinction is one of the main criteria on our page on how to choose a retatrutide vendor.
Are peptides illegal in any states?
Drug approval is federal. The Federal Food, Drug, and Cosmetic Act decides whether a product may be sold as a drug anywhere in the United States, and the FDA enforces it nationwide. States layer their own rules on pharmacy practice, compounding and the practice of medicine, which bear mainly on clinics and compounders. We have not found, and do not maintain, a verified list of state laws that single out research peptides, so we will not invent one; if you have a specific state question, check that state's pharmacy board and consult a lawyer.
What does research use only mean for a buyer?
It means the product is a reagent, not a medicine. A research-use-only peptide has not been manufactured under the standards that apply to drugs, has not been reviewed by any regulator for safety in people, and is sold on the condition that it will be used in a laboratory. The vendor's terms will say that. A buyer who agrees to those terms and uses the material for anything else is outside both the vendor's terms and the framing that makes the sale lawful.
It also means the buyer should expect research-supplier behavior from the vendor: a molecule named by its identifiers, a lyophilized powder in a sealed vial, storage guidance, and no instructions for use in people. Our reta peptide page explains what retatrutide is and what Lilly is investigating it for, without claims.
Where do research buyers get retatrutide?
From research suppliers that sell it as a reagent. Among the vendors we compare, Astral is our pick: it synthesizes and manufactures its peptides in the United States, ships from its own New York inventory, sells GLP-3 RT in 10, 20 and 30 mg vials at $67.99, $117.99 and $157.99, and keeps its product page to research-use language with no claims about people, which is the posture this page describes. On those points it is in a class of its own.
Common questions
Can you legally buy peptides now?
Research peptides are sold to laboratories for research use only, and that market operates openly in the US. What is not lawful is selling an unapproved peptide as a treatment for people. The FDA has sent warning letters to online sellers whose sites described uses in people, so buy from a supplier that stays inside research-use terms.
Is retatrutide available for sale?
As a research reagent it is: several US research suppliers sell it as a lyophilized powder for laboratory use. As a medicine it is not: there is no approved retatrutide product, no pharmacy carries one, and Lilly supplies the compound only through its trials and its physician-initiated expanded access program.
Are peptides illegal in any states?
Federal law governs whether a drug may be sold in the United States, and it applies in every state. States add their own pharmacy, compounding and practice rules, which mainly affect clinics and compounders rather than laboratory purchases. We do not keep a state-by-state list, so check your own state's rules if you are unsure.
When will reta be available?
Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027. Review follows submission, and Lilly has not announced an approval date. Until approval, retatrutide is available only inside Lilly's trials, through its expanded access program, or as a research reagent for laboratories.
Can I get retatrutide through a clinical trial?
Lilly's retatrutide program is listed on ClinicalTrials.gov under the compound code LY3437943, with phase 3 trials in obesity, type 2 diabetes and related conditions. Several are still active but no longer recruiting. Trial entry runs through study sites and their eligibility criteria, not through any vendor.